Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / ALT - Altimmune's Pemvidutide Is Not To Be Dismissed

ALT - Altimmune's Pemvidutide Is Not To Be Dismissed

Altimmune Inc.

2024-05-28 16:13:42 ET

Summary

  • Altimmune is developing pemvidutide, a dual agonist of GLP-1 and glucagon receptors, with promising phase 2 data already seen in obesity.
  • A phase 2 trial in metabolic dysfunction-associated steatohepatitis, or MASH, is underway, and set to produce a readout in Q1'25.
  • Altimmune also has an end-of-phase 2 meeting with the US FDA in Q3'24, which could provide clarity on requirements for a phase 3 program in obesity.

...

For further details see:

Altimmune's Pemvidutide Is Not To Be Dismissed
Stock Information
Company Name: Altimmune Inc.
Stock Symbol: ALT
Market: NASDAQ
Website: altimmune.com
Menu
ALT ALT Quote ALT Short ALT News ALT Articles ALT Message Board
Get ALT Alerts

News, Short Squeeze, Breakout and More Instantly...